Why Monitor Liver Tests with Tigecycline?
Tigecycline, a glycylcycline antibiotic for serious infections like complicated skin infections and intra-abdominal infections, carries a risk of hepatotoxicity. Liver function tests (LFTs) help detect elevated enzymes signaling potential liver injury early.
Key Liver Tests to Monitor
- ALT (alanine aminotransferase) and AST (aspartate aminotransferase): Primary markers for hepatocellular injury. Tigecycline labeling notes increases in these enzymes in up to 15% of patients, more common in those with liver impairment or prolonged use.[1][2]
- ALP (alkaline phosphatase) and bilirubin: Track cholestatic or mixed liver injury. Elevations occur in 3-10% of cases, with bilirubin rises indicating severe issues.[1]
- Full LFT panel baseline and periodic checks: Guidelines recommend baseline LFTs before starting tigecycline, then weekly or biweekly during treatment, especially beyond 14 days or in at-risk patients (e.g., hepatic disease, alcohol use).[2][3]
When Elevations Occur and What to Watch For
Enzyme elevations are often asymptomatic and reversible upon discontinuation, peaking 7-14 days into therapy. Severe cases (e.g., ALT >10x upper limit) may require stopping the drug. No specific cutoff mandates cessation, but trends matter—rising ALT/AST despite stable bilirubin signals closer monitoring.[1][3]
Patients at Higher Risk
Those with baseline liver dysfunction, obesity, or concurrent hepatotoxins (e.g., other antibiotics, statins) see higher rates. No dose adjustment for mild-moderate impairment, but avoid in severe cases.[2]
Alternatives if Liver Issues Arise
Switch to drugs like meropenem or vancomycin with lower hepatotoxicity profiles. Tigecycline's broad-spectrum coverage against multidrug-resistant bugs justifies its use when LFTs stay stable.[3]
[1]: FDA Tigecycline (Tygacil) Prescribing Information, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021821s032lbl.pdf
[2]: Clinical Pharmacology Review, Tigecycline. https://www.ncbi.nlm.nih.gov/books/NBK570945/
[3]: IDSA Guidelines on Antimicrobial Use, Hepatology Monitoring. https://academic.oup.com/cid/article/73/2/e1024/5909460